{
    "nct_id": "NCT03792516",
    "official_title": "A Phase I Proof-of-Concept Study of Artesunate Ointment for the Treatment of Patients With High-Grade Vulvar Intraepithelial Neoplasia (HSIL VIN 2/3)",
    "inclusion_criteria": "* Colposcopically-directed biopsy diagnosis of high-grade vulvar dysplasia (VIN2, VIN3, VIN2/3, HSIL), including both new and recurrent disease.\n* Females of childbearing potential: negative urine pregnancy test\n* Ability to provide informed consent\n* Ability to collaborate with planned follow-up (transportation, compliance history, etc.)\n* Use of contraception through the study exit visit (week 28)\nHealthy volunteers allowed\nMust be FEMALE\nMust have minimum age of 18 Years\nMust have maximum age of 100 Years",
    "exclusion_criteria": "* Concomitant use of any topical immune modulating agents e.g. imiquimod, Aldara Â®\n* Cluster of differentiation 4 (CD4) count < 200 at the time of screening for eligibility.\n* Unable to provide informed consent\n* Currently receiving systemic chemotherapy or radiation therapy for another cancer.\n* Pregnant females\n* Concurrent dermatological disorders involving the vulva (i.e., herpes, ulceration secondary to Crohn's disease) or vulvar dermatosis (i.e., lichen planus, lichen sclerosus, or lichen simplex chronicus);\n* Women weighing less than 50 kg",
    "miscellaneous_criteria": ""
}